November 2024

Comparison of EasyM Clonotypic Mass Spectrometry and EuroFlow MRD in Multiple Myeloma

2025-02-18T16:57:33-05:00November 7th, 2024|Publication|

Introduction In this case study, we summarize a retrospective comparison of EasyM and Euroflow NGF for MRD in newly diagnosed multiple myeloma patients.  Minimal residual disease (MRD) negativity is a critical measure of therapeutic response in multiple myeloma (MM) and is strongly associated with improved progression-free and overall survival. The IMWG (International [...]

September 2021

A Personalized Mass Spectrometry–Based Assay to Monitor M-Protein in Patients with Multiple Myeloma (EasyM)

2025-02-18T16:57:57-05:00September 15th, 2021|Publication|

Mariya Liyasova, Zac McDonald, Paul Taylor, Kathleen Gorospe, Xin Xu, Chenyu Yao, Qixin Liu, Liqiang Yang, Eshetu G Atenafu, Giovanni Piza, Bin Ma, Donna Reece, Suzanne Trudel  DOI: 10.1158/1078-0432.CCR-21-0649 Publication Summary M-protein is a well-established biomarker used for multiple myeloma monitoring.  Current improvements in multiple myeloma treatment created the need to monitor minimal residual disease (MRD) with high sensitivity. Measuring residual levels of [...]

August 2021

Mass Spectrometry Provides a Highly Sensitive Noninvasive Means of Sequencing and Tracking M-Protein in the Blood of Multiple Myeloma Patients

2025-02-18T16:58:19-05:00August 6th, 2021|Publication|

Zac McDonald, Paul Taylor, Mariya Liyasova, Qixin Liu, Bin Ma DOI: 10.1021/acs.jproteome.0c01022 Publication Summary The amino acid sequence of the M-protein for multiple myeloma is unique compared to the polyclonal antibodies in patients’ blood. This uniqueness is exploited to develop an ultrasensitive M-protein detection method utilizing mass spectrometry (MS). This study demonstrates [...]

Go to Top